Home › NCT05858645

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

About the study

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

What is being tested

• deucravacitinib (drug)

Sponsor: University of California, San Francisco · Participants: 25 · Started: Oct 1, 2023

Contact the study team

• Raymond Cho, MD, PhD · Phone: 415 575 0524

Official record on ClinicalTrials.gov — NCT05858645

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.